Stereotaxis, Inc. 8-K

What Happened

• Stereotaxis announced it completed the acquisition of Robocath (share sale agreement dated April 14, 2026) on July 7, 2026 for approximately $20 million in cash and stock. A press release announcing the closing was furnished on July 9, 2026.
• At closing, Stereotaxis issued 1,469,485 shares of common stock and issued pre‑funded purchaser warrants entitling holders to buy 4,575,143 shares (exercise price equal to the $0.001 par value per share). The purchaser warrants are exercisable from issuance until July 7, 2031.
• The company also issued 225,000 shares to Robocath’s financial advisor as partial payment of a success fee.

Key Details

• Upfront deal consideration: ~ $20 million (cash and common stock) paid at closing (July 7, 2026).
• Stock/warrant specifics: 1,469,485 common shares issued; 4,575,143 pre‑funded purchaser warrants issued; warrants exercisable through July 7, 2031 at par value.
• Potential additional payments: up to $25.0 million aggregate in earnout consideration (cash or stock, or purchaser warrants if electable), dependent on performance milestones, working capital/price adjustments and indemnity offsets.
• Registration and limits: Issuances were made under exemptions from registration (Section 4(a)(2), Rule 506(b), and/or Regulation S). Stereotaxis must file a resale registration statement covering the upfront stock consideration and its good‑faith estimate of shares potentially issuable under milestones. The company will not issue more than 19.9% of pre‑issuance outstanding shares to Robocath securityholders/financial advisor without shareholder approval.

Why It Matters

• The acquisition expands Stereotaxis’s product and commercial footprint through ownership of Robocath and involves meaningful equity dilution potential (upfront shares/warrants plus up to $25M of contingent consideration).
• Investors should note the resale registration filing requirement for the stock consideration (which enables secondary sales) and the timeline and caps on warrant exercise and future issuance; earnout outcomes and any working‑capital adjustments will affect future dilution and cash needs.
• The transaction terms (cash, stock, warrants, and contingent payments) are concrete near‑term impacts on Stereotaxis’s capital structure and potential future share count—important for shareholders tracking dilution and the company’s integration of Robocath.